CureVac vs Moderna Which Is More Lucrative?

CureVac and Moderna are two prominent companies in the biotechnology industry that have gained significant attention for their efforts in developing mRNA vaccines, particularly in the fight against the COVID-19 pandemic. Both companies have seen their stocks experience a high level of volatility due to the rapidly changing landscape of the healthcare sector and the potential for breakthroughs in vaccine technology. Investors are closely watching the performance of CureVac and Moderna stocks as they navigate the uncertainties of the market and advancements in medical research.

CureVac or Moderna?

When comparing CureVac and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between CureVac and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. CureVac has a dividend yield of -%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. CureVac reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with CureVac P/E ratio at 6.10 and Moderna's P/E ratio at -7.24. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. CureVac P/B ratio is 0.93 while Moderna's P/B ratio is 1.35.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, CureVac has seen a 5-year revenue growth of 2.33%, while Moderna's is 10.87%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with CureVac's ROE at 21.40% and Moderna's ROE at -17.68%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $3.12 for CureVac and $41.38 for Moderna. Over the past year, CureVac's prices ranged from $2.21 to $6.30, with a yearly change of 184.42%. Moderna's prices fluctuated between $35.80 and $170.47, with a yearly change of 376.17%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.